Chartered Patent Attorney
European Patent Attorney
Fiona graduated with a Masters Degree in Natural Sciences at the University of Cambridge. She specialised in chemistry, physiology and pharmacology. She also obtained her certificate of Intellectual Property Law at Queen Mary University of London.
Fiona joined GJE in 2005. She qualified as both a Chartered Patent Attorney and European Patent Attorney in 2010. She became a partner in 2015.
Fiona handles a wide variety of work in the pharmaceutical, chemical and biotechnology fields. She has drafted and prosecuted applications relating to gene therapy, drug re-profiling, medical devices, novel therapeutic compounds, polymer chemistry and fuel cells. She has also obtained Supplementary Protection Certificates (SPCs) for approved drugs in a number of jurisdictions worldwide. She leads the firm’s SPC team and regularly writes articles on the topic.
The majority of Fiona’s work involves working with UK clients, and she therefore has extensive experience in drafting new applications and handling large worldwide patent portfolios. Fiona makes sure her clients are “Due Diligence ready”; she has helped many companies through successful investment rounds, and has particular expertise in drafting IP reports for that purpose.
Fiona also enjoys the excitement of working with start-up companies and ensures that her clients understand the importance of matching IP strategy to the business plan from the beginning. As recognised by Legal 500, Fiona “makes efforts to really understand not only the technology involved but also the business.”
Fiona is a regular attendee at FICPI and AIPLA overseas conferences and also lectures on the CIPA Administrator course. In 2017, Fiona was recognised as one of Management Today’s ’35 under 35′ for her accomplishments in intellectual property. Fiona has successfully guided clients in the Biotechnology and Pharmaceutical industries through multiple fund-raising rounds and partnering successes, helping them raise well in excess of £200 million in investment the last three years alone.